Advaxis (ADXS) Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca's (AZN) IMFINZI

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ACN
3. NVDA
4. GOOGL
5. MU
6. DFTX
7. USO
8. APGE
9. ABBV
10. NAVN

Go back to Advaxis (ADXS) Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca's (AZN) IMFINZI

Advaxis Reports Fiscal 2018 First Quarter Financial Results and Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca’s IMFINZI® (Durvalumab)

March 12, 2018 4:05 PM EDT

Conference call to be held today at 4:30 p.m. Eastern time

PRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announces financial results for the three months ended January 31, 2018 and provides a business update.

Recent Key... More